Hematopathology Fellowship Program

The Hematopathology Fellowship Program at City of Hope is a two-year program primarily designed for fellows interested in academic hematopathology.  Supporting one of the largest bone marrow transplantation programs in the United States, and enjoying an active consultation service, the division evaluates more than 3,000 diagnostic specimens involving peripheral blood, bone marrow, lymph nodes and extranodal biopsies each year.  The program has a rich history, which includes notable past faculty such as Drs. Henry Rappaport, Daniel Arber, and Lawrence Weiss.  Multiparameter studies are emphasized, including analyses by morphology, immunohistochemistry, flow cytometry, and cytogenetic and molecular techniques, all supported by active in-house laboratories. 
 
The first fellowship year is Accreditation Council for Graduate Medical Education (ACGME) accredited, and focuses on diagnostic hematopathology.  Didactic lectures, Pathology Grand Rounds , slide seminars, patient care conferences, bimonthly research meetings, and journal club are part of the educational experience.  During the second year, fellows continue their research projects and participate as instructors in independent hematopathology case signout within the division, preparing them for academic careers.
 
Contact Information
 
City of Hope National Medical Center
Hematopathology Coordinator - Department of Pathology
1500 E. Duarte Road
Duarte, CA 91010
 
Phone (626) 256-4673  ext. 62456
 
Program Faculty
 
 
 
 
 
 
 
 
 
 
 
Requirements
 
Candidates must be in good standing in an ACGME accredited program in Anatomic and Clinical Pathology, (or equivalent program in Canada recognized by American Board of Pathology), and be eligible for Pathology Boards and a California medical license upon completion of residency training.
 
Positions and Application Process
 
Up to 3 ACGME accredited positions are available each year.  For positions beginning in July, please send a brief cover letter, three (3) reference letters, and C.V. (or standardized fellowship application from CAP) at least a year and a half in advance (e.g. September 2016 for a July 2018 start date) to:
 
City of Hope National Medical Center
Attn: Alejandra Baldrias
Hematopathology Coordinator - Department of Pathology
1500 E. Duarte Road
Duarte, CA  91010
626-256-4673, ext. 62456
 
Select Presentations and Publications Written by Faculty and Fellows
 
Low L, Song JY, Chen YY, Valle M, Weisenburger DD, Kim YS.  Coexpression of MYC and BCL2 Proteins Identifies a Subset of Follicular Lymphoma that Undergoes Transformation to Diffuse Large B-cell Lymphoma and Correlates with Poor Overall Survival (USCAP 2016).

Ameri M, Wong J, Low L, Chen YY, Weisenburger DD, Pillai R, Kim YS, Song JY.  CXCR4 Expression in Follicular Lymphoma (USCAP 2016).

Song L, Feldman AL, Murata-Collins J, Bedell V, Nathwani BN, Weisenburger DD, Song JY.  Cyclin D1 expression in T cell lymphomas (USCAP 2015 platform presentation).

Low L, Song JY, Mei M, Krishnan A, Nademanee A, Popplewell L, Chen R, Spielberger R, Cai J, Chen YY, Zumel S, Gaal K, Aoun P, Weisenburger DD, Kim YS.  Coexpression of MYC and BCL2 protein in diffuse large B cell lymphoma predicts a poor outcome in patients treated with autologous hematopoietic stem cell transplantation (USCAP 2015).

Batra R, Weisenburger D, Snyder D, Bedell V, Murata-Collins J, Gaal K. Prognostic Significance of Chromosomal Aberrations in Philadelphia Chromosome Negative Metaphases during Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myelogenous Leukemia (USCAP 2014).

Zhang N, Reddi DM, Weisenburger DD, Kim Y.  Follicular Lymphoma with Marginal Zone Differentiation, an Institutional Experience (USCAP 2014).

Bautista-Quach MA, Nademanee A, Weisenburger DD, Chen W, Kim YS. Implant-associated primary anaplastic large-cell lymphoma with simultaneous involvement of bilateral breast capsules. Clin Breast Cancer. 2013;13(6):492-495. PMID 24267734

Kim YS, Wu H, Pawlowska AB, Bautista-Quach MA, Huang Q, Gaal K, Chang KL. Pediatric mast cell sarcoma of temporal bone with novel L799F (2395 C>T) KIT mutation, mimicking histiocytic neoplasm. Am J Surg Pathol. 2013;37(3):453-458. PMID 23388130

Pan ZG, Zhang QY, Lu ZB, Quinto T, Rozenvald IB, Liu LT, Wilson D, Reddy V, Huang Q, Wang HY, Ren YS. Extracavitary KSHV-associated large B-Cell lymphoma: a distinct entity or a subtype of primary effusion lymphoma? Study of 9 cases and review of an additional 43 cases. Am J Surg Pathol. 2012;36(8):1129-1140.  PMID 22790853

Rausei-Mills V, Chang KL, Gaal KK, Weiss LM, Huang Q.  Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation. Am J Clin Pathol 2008; 129(4):624-9.  PMID 18343790

Program Graduates
 
2015
Liping Song, Midwest Pathology Associates
 
2014
Rashmi Batra, Santa Clara Valley Medical Center
Deepti Reddi, University of Washington
Nan Zhang, University of Buffalo
Kali Freeman, Yosemite Pathology Group
Tobi Quinto, UCLA Surgical Pathology Fellowship
 
2013
Marnelli Aguilar Bautista-Quach, Yosemite Pathology Group
 
2012
Hannah Wong, Diagnostic Pathology Medical Group
Zenggang Pan, University of Colorado, Denver
Aihong Liu, University of San Francisco
 
2011
Ji Lu, Kaiser Permanente, Northern California
Jyotsna Reddy, Kaiser Permanente, Sacramento
 
2010
Hung Luu, University of Texas, Southwestern
Mingyi Chen, University of California, Davis
Renuka Agrawal, Clarient
 
2009
Youn Kim, Kaiser Permanente, Bellflower
Monica Caro-Mosquera, Hoag Memorial Hospital
Angie Pham, Seattle, WA
 
2008
Steve Lum, The Queen's Medical Center
Kate Grimm, Clarient
 
2007
Veronica Rausei-Mills, Hoag Memorial Hospital
Sherif Rezk, University of California, Irvine